tezepelumab

Home
Ligands
tezepelumab

GtoPdb Ligand ID: 8933

tezepelumab is an approved drug (FDA (2021), ENA (2022))

Comment: Tezepelumab is a fully human IgG2λ monoclonal antibody, that is a potential first-in-class agent that blocks the epithelial-cell-derived cytokine thymic stromal lymphopoietin (TSLP- which is an upstream modulator of multiple inflammatory pathways). It is being investigated for its immunomodulatory action.

Immunopharmacology Comments
Positive Phase 2 (NCT02054130) results in adult patients with noneosinophilic type asthma that is poorly controlled by long-acting β-agonists and medium-to-high doses of inhaled glucocorticoids were reported by Corren et al. in 2017 [2]. Positive results showing efficacy in Phase 3 studies in asthma patients were published in 2020 [4,8], but the mAb has failed in atopic dermatitis trials [1].

Immunopharmacology Comments

Positive Phase 2 (NCT02054130) results in adult patients with noneosinophilic type asthma that is poorly controlled by long-acting β-agonists and medium-to-high doses of inhaled glucocorticoids were reported by Corren et al. in 2017 [2]. Positive results showing efficacy in Phase 3 studies in asthma patients were published in 2020 [4,8], but the mAb has failed in atopic dermatitis trials [1].

Immunopharmacology Disease
Disease	X-Refs	Comment	References
Atopic dermatitis	Disease Ontology: DOID:3310 OMIM: 603165	Clinical candidate for atopic dermatitis (Phase 1).
Asthma	Disease Ontology: DOID:2841 OMIM: 600807	Clinical candidate for asthma (Phase 2).